BBLG News & Events

Bone Biologics announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 2,112,677 shares of common stock (or pre-funded warrants in lieu thereof), Series F warrants to purchase up to 2,112,677 shares of common stock and short-term Series G warrants to purchase up to 2,112,677 shares of common stock at a purchase price of $1.42 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Bone Biologics announced that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the company reported in December 2025. The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the company progresses rhNELL-1 toward the manufacturing scale required for a future pivotal study.

Bone Biologics summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. 2025 Highlights: Extended rhNELL-1 Product Shelf Life; SCompleted a registered public offering for total gross proceeds of $5 million during the second quarter of 2025; filed a U.S. patent application related to its bone regeneration technology based on recombinant human NELL-1; regained compliance with Nasdaq's minimum bid price requirement. Outlook for 2026: Clinical Development Progression - Continuing advancement of NB1, the Company's rhNELL-1-based bone graft product candidate, including the expected completion of patient enrollment in its first-in-human clinical trial and potential interim updates, as appropriate; Operational and Manufacturing Execution - Ongoing efforts to support regulatory readiness and future commercialization planning; Intellectual Property Strategy - Continuing pursuit of relevant patent protections to enhance long-term platform value; Financial Discipline and Strategic Focus - Maintaining prudent capital management while supporting scientific progress and shareholder engagement.

Bone Biologics announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. "The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life milestones," the company said. Achieving a 24-month shelf life is expected to enhance manufacturing efficiency, inventory management, supply-chain flexibility, and clinical and commercial readiness as the Company advances rhNELL-1 through development.